MX2023000276A - Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica. - Google Patents
Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica.Info
- Publication number
- MX2023000276A MX2023000276A MX2023000276A MX2023000276A MX2023000276A MX 2023000276 A MX2023000276 A MX 2023000276A MX 2023000276 A MX2023000276 A MX 2023000276A MX 2023000276 A MX2023000276 A MX 2023000276A MX 2023000276 A MX2023000276 A MX 2023000276A
- Authority
- MX
- Mexico
- Prior art keywords
- zibotentan
- treatment
- combination
- dapagliflozin
- kidney disease
- Prior art date
Links
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 title abstract 2
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003834 dapagliflozin Drugs 0.000 title abstract 2
- 229950003684 zibotentan Drugs 0.000 title abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 title 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 2
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 2
- 102000002045 Endothelin Human genes 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 abstract 1
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente descripción se refiere al antagonista del receptor de endotelina (ERA) zibotentan en combinación con el inhibidor de cotransportador 2 de glucosa dependiente de sodio (SGLT-2) dapagliflozina para su uso en el tratamiento de ciertas enfermedades relacionadas con endotelina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050147P | 2020-07-10 | 2020-07-10 | |
| US202163196793P | 2021-06-04 | 2021-06-04 | |
| PCT/IB2021/056177 WO2022009163A1 (en) | 2020-07-10 | 2021-07-09 | Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000276A true MX2023000276A (es) | 2023-02-09 |
Family
ID=76959008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000276A MX2023000276A (es) | 2020-07-10 | 2021-07-09 | Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11730735B2 (es) |
| EP (1) | EP4178578A1 (es) |
| JP (1) | JP2023541766A (es) |
| KR (1) | KR20230038234A (es) |
| CN (1) | CN115803028A (es) |
| AU (1) | AU2021305983A1 (es) |
| BR (1) | BR112023000406A2 (es) |
| CA (1) | CA3188345A1 (es) |
| CL (1) | CL2023000097A1 (es) |
| CR (1) | CR20230083A (es) |
| DO (1) | DOP2022000301A (es) |
| IL (1) | IL299568A (es) |
| MX (1) | MX2023000276A (es) |
| PE (1) | PE20230778A1 (es) |
| TW (1) | TW202216147A (es) |
| UY (1) | UY39321A (es) |
| WO (1) | WO2022009163A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR122917A1 (es) * | 2020-07-10 | 2022-10-12 | Astrazeneca Ab | Combinación de zibotentan y dapagliflozina para el tratamiento de enfermedades relacionadas con endotelina |
| WO2024033519A1 (en) * | 2022-08-12 | 2024-02-15 | Astrazeneca Ab | Combination therapies for treatment of cirrhosis with portal hypertension |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| CN105517541A (zh) | 2013-07-08 | 2016-04-20 | 艾伯维公司 | 包含阿曲生坦的稳定化药物剂型 |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| WO2018153513A1 (en) | 2017-02-27 | 2018-08-30 | Idorsia Pharmaceuticals Ltd | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
| MX2020005543A (es) | 2017-11-30 | 2020-08-20 | Idorsia Pharmaceuticals Ltd | Combinacion de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina. |
| JP2022511380A (ja) | 2018-10-01 | 2022-01-31 | アストラゼネカ・アクチエボラーグ | 血清尿酸を低減させるための組成物 |
| US20230270718A1 (en) | 2020-04-10 | 2023-08-31 | Chinook Therapeutics, Inc. | Methods of treating diabetic kidney disease |
-
2021
- 2021-07-09 CR CR20230083A patent/CR20230083A/es unknown
- 2021-07-09 EP EP21742896.0A patent/EP4178578A1/en active Pending
- 2021-07-09 PE PE2023000028A patent/PE20230778A1/es unknown
- 2021-07-09 IL IL299568A patent/IL299568A/en unknown
- 2021-07-09 MX MX2023000276A patent/MX2023000276A/es unknown
- 2021-07-09 JP JP2023501052A patent/JP2023541766A/ja active Pending
- 2021-07-09 CA CA3188345A patent/CA3188345A1/en active Pending
- 2021-07-09 BR BR112023000406A patent/BR112023000406A2/pt unknown
- 2021-07-09 WO PCT/IB2021/056177 patent/WO2022009163A1/en active Application Filing
- 2021-07-09 AU AU2021305983A patent/AU2021305983A1/en active Pending
- 2021-07-09 TW TW110125259A patent/TW202216147A/zh unknown
- 2021-07-09 KR KR1020237004545A patent/KR20230038234A/ko unknown
- 2021-07-09 CN CN202180049043.7A patent/CN115803028A/zh active Pending
- 2021-07-09 US US17/371,162 patent/US11730735B2/en active Active
- 2021-07-12 UY UY0001039321A patent/UY39321A/es unknown
-
2022
- 2022-12-29 DO DO2022000301A patent/DOP2022000301A/es unknown
-
2023
- 2023-01-10 CL CL2023000097A patent/CL2023000097A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230083A (es) | 2023-05-16 |
| CN115803028A (zh) | 2023-03-14 |
| US11730735B2 (en) | 2023-08-22 |
| AU2021305983A1 (en) | 2023-03-02 |
| WO2022009163A1 (en) | 2022-01-13 |
| CL2023000097A1 (es) | 2023-09-01 |
| US20220023295A1 (en) | 2022-01-27 |
| BR112023000406A2 (pt) | 2023-01-31 |
| JP2023541766A (ja) | 2023-10-04 |
| KR20230038234A (ko) | 2023-03-17 |
| TW202216147A (zh) | 2022-05-01 |
| IL299568A (en) | 2023-02-01 |
| DOP2022000301A (es) | 2023-01-31 |
| UY39321A (es) | 2022-01-31 |
| PE20230778A1 (es) | 2023-05-09 |
| CA3188345A1 (en) | 2022-01-13 |
| EP4178578A1 (en) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230083A (es) | Combinación de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal crónica | |
| Yaqinuddin et al. | Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents | |
| Chen et al. | Sargassum fusiforme polysaccharides inhibit VEGF-A-related angiogenesis and proliferation of lung cancer in vitro and in vivo | |
| Murakami et al. | Chemokine receptors and melanoma metastasis | |
| Bar-Yehuda et al. | The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis | |
| RU2011115406A (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
| DE602004028228D1 (de) | Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten | |
| SV2006002342A (es) | Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida | |
| NI200700174A (es) | Terapia combinatoria para el tratamiento de la diabetes y de condiciones relacionadas con la misma o para el tratamiento de condiciones mejoradas aumentando un nivel de glp-1 en sangre. | |
| MX2010005081A (es) | Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco. | |
| CL2008002207A1 (es) | Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04). | |
| MX2007004749A (es) | Uso de agosnitas de receptor a2a de adenosina. | |
| NO20062739L (no) | Kontrollert frigivining av topirimat i flytende doseringsform | |
| WO2008083200A3 (en) | Spiroheterocyclic glycosides and methods of use | |
| DE60202278D1 (de) | Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten | |
| ATE454148T1 (de) | Acylierte piperidinderivative als melanocortin-4- rezeptoragonisten | |
| Wu et al. | The inhibitory effect of doxycycline on cisplatin-sensitive and-resistant epithelial ovarian cancer | |
| CL2007001748A1 (es) | Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras. | |
| DE602006013792D1 (de) | Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika | |
| DE602006011959D1 (de) | Na+, k+-atpase-expression bei zervixdysplasie und -krebs | |
| BR112023016680A2 (pt) | Terapias de combinação com anticorpos anti-cd38 e parp ou inibidores de receptor de adenosina | |
| Jain et al. | Novel therapeutic options for relapsed hairy cell leukemia | |
| CL2008002278A1 (es) | Metodo para el tratamiento de una enfermedad ocular relacionada al tnfalfa; metodo para la atenuacion de la expresion del arnm de tace o tnfr1 en el ojo de un paciente. | |
| AR041595A1 (es) | Tratamiento terapeutico | |
| Nyunt et al. | Immune response to fungi in diabetic patients with invasive fungal rhinosinusitis |